Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

Investigators created a prognostic digital pathology-based AI score to identify a subset of patients with clinically high-risk prostate cancer more likely to benefit from the addition of abiraterone ...

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Medical AI tools for clinicians and patients have advantages and disadvantages, including implicit bias in triage and virtual urgent care.

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

Real-world data confirm PSA cutoffs for prognosis in patients treated for metastatic hormone-sensitive prostate cancer.

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...

Only incidence and prevalence rates attributable to keratinocyte cancer, DALYs attributable to BCC would increase by 2050. (HealthDay News) — Older adults have a substantial and increasing ...

The mean monthly launch price increased from $10,954 to $27,891. The prices charged at the US launch of targeted cancer therapies have increased well above the rate of inflation every year since ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes. (HealthDay News) — For adults with diabetes and obesity, glucagon ...